• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B†‡

  1. Maurizia Rossana Brunetto1,§,*,
  2. Francesco Moriconi1,
  3. Ferruccio Bonino2,
  4. George K. K. Lau3,
  5. Patrizia Farci4,
  6. Cihan Yurdaydin5,
  7. Teerha Piratvisuth6,
  8. Kangxian Luo7,
  9. Yuming Wang8,
  10. Stephanos Hadziyannis9,
  11. Eva Wolf10,
  12. Philip McCloud11,
  13. Richard Batrla12,
  14. Patrick Marcellin13

Article first published online: 2 DEC 2008

DOI: 10.1002/hep.22760

Issue

Hepatology

Hepatology

Volume 49, Issue 4, pages 1141–1150, April 2009

Additional Information

How to Cite

Brunetto, M. R., Moriconi, F., Bonino, F., Lau, G. K. K., Farci, P., Yurdaydin, C., Piratvisuth, T., Luo, K., Wang, Y., Hadziyannis, S., Wolf, E., McCloud, P., Batrla, R. and Marcellin, P. (2009), Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology, 49: 1141–1150. doi: 10.1002/hep.22760

Author Information

  1. 1

    UO Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  2. 2

    Scientific Direction, Foundation IRCCS Policlinico of Milan and University of Pisa, Italy

  3. 3

    Department of Medicine, Queen Mary Hospital, Hong Kong, China

  4. 4

    Dipartimento di Scienze Mediche, Università di Cagliari, Monserrato, Italy

  5. 5

    Department of Gastroenterology, University of Ankara, Turkey

  6. 6

    Department of Internal Medicine, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand

  7. 7

    Department of Infectious Diseases, Nanfang Hospital, Guangzhou, China

  8. 8

    Infectious Disease Department, Xinan Hospital, Chongqing, China

  9. 9

    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece

  10. 10

    MUC Research, Munich, Germany

  11. 11

    Roche, Dee Why, Australia

  12. 12

    Roche, Basel, Switzerland

  13. 13

    Hôpital Beaujon, University of Paris, Clichy, France

  1. §

    fax: (39)-050-995457

*UO Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  1. †

    See Editorial on Page 1063

  2. ‡

    Potential conflict of interest: Dr. Brunetto is on the speakers' bureau of Roche. Dr. Bonino is a consultant for, advises, and is on the speakers' bureau of Abbott, Bristol-Myers Squibb, Gilead, and Novartis. He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on the speaker's bureau of GlaxoSmith Kline. Dr. Hadziyannis is on the speakers' bureau of and received grants from Roche. He advises and received grants from Gilead. He advises Novartis and Bristol-Myers Squibb. Dr. McCloud owns stock in Roche.

  3. §

    fax: (39)-050-995457

Publication History

  1. Issue published online: 27 MAR 2009
  2. Article first published online: 2 DEC 2008
  3. Accepted manuscript online: 2 DEC 2008 12:00AM EST
  4. Manuscript Accepted: 23 NOV 2008
  5. Manuscript Received: 25 JUN 2008

Funded by

  • Roche

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (748K)

References

  • 1
    Hui CK, Lau GK. Current issues and future directions in treatment. Semin Liver Dis 2006; 26: 192–197.
  • 2
    Chen G, Lin W, Shen F, Iloeje UH, London WT. Chronic hepatitis B infection and mortality from non-liver causes: results from the Haimen cohort study. Int J Epidemiol 2005; 34: 132–137.
  • 3
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35: 1522–1527.
    Direct Link:
  • 4
    Niederau C, Heintges T, Lange T, Oldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–1427.
  • 5
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617–624.
    Direct Link:
  • 6
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–270.
  • 7
    Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756–763.
    Direct Link:
  • 8
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857–861.
    Direct Link:
  • 9
    The EASL Jury. EASL International Consensus Conference on Hepatitis B, 13–14 September, 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003; 39: S3–S25.
  • 10
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507–539.
    Direct Link:
  • 11
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93: 896–900.
    Direct Link:
  • 12
    Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45–52.
  • 13
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695.
  • 14
    Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123–129.
  • 15
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with for HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–1217.
  • 16
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673–2681.
  • 17
    Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73–82.
  • 18
    Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Monterey: Wadsworth and Brooks/Cole, 1984.
  • 19
    Steinberg D, Colla P. CART—Classification and Regression Trees. San Diego, CA: Salford Systems, 1997.
  • 20
    Korevaar A, Moucari R, Asselah T, Lada O, Boyer N, Martinot-Peignoux M, et al. High rates of HBsAg seroconversion ion chronic hepatitis B patients responding to interferon therapy: a long term follow-up study [Abstract]. HEPATOLOGY 2006: 46: 679A.
  • 21
    Colombatto P, Civitano L, Bizzarri R, Oliveri F, Choudhury S, Gieschke R, et al; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther 2006; 11: 197–212
  • 22
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al.; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.
  • 23
    Shouval D, Akarca US, Hatzis G, Kitis G, Lai CL, Cheinquer H, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). J Hepatol 2006; Suppl: 45A.
  • 24
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al.; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–1751.
  • 25
    Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251–257.
  • 26
    Keeffe EB, Dieterich DT, Han S-H, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.
  • 27
    Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 2718–2723.
    Direct Link:
View Full Article with Supporting Information (HTML) Get PDF (748K)